{
    "@context": "https://schema.org",
    "@type": "Article",
    "headline": "Psychedelic Breakthroughs: Key Considerations for Clinical Trials",
    "url": "https://www.lexblog.com/2024/01/25/psychedelic-breakthroughs-key-considerations-for-clinical-trials/",
    "identifier": {
        "@type": "PropertyValue",
        "name": "LexBlog Library record",
        "value": "LEX-WK-V1RFPQ1R",
        "url": "https://www.lexblog.com/lib/V1RFPQ1R/"
    },
    "datePublished": "2024-01-25T14:06:43-05:00",
    "dateModified": "2024-01-26T11:21:50-05:00",
    "author": {
        "@type": "Person",
        "name": "Kimberly Chew, Natasha Sumner"
    },
    "sourceOrganization": {
        "@type": "Organization",
        "name": "Husch Blackwell LLP"
    },
    "organizationScope": "at-publication",
    "isPartOf": "Healthcare Law Insights",
    "about": "Health Care and Life Sciences · Technology and AI",
    "sourceUrl": "https://www.healthcarelawinsights.com/?p=5753",
    "sourceStability": "may-move"
}